Table 3

a and b Most frequent combinations of at least two and three substances
a.
Lithium SSRI 9.2%
Valproic acid SSRI 7.2
Lithium Mirtazapine 5.8
Lithium Venlafaxine 5.7
Quetiapine SSRI 5.2
Quetiapine Lithium 5.1
Lamotrigine SSRI 4.9
Valproic acid Venlafaxine 4.6
Valproic acid Mirtazapine 4.5
Valproic acid Lithium 4.1
Quetiapine Lamotrigine 3.9
SSRI Mirtazapine 3.8
Olanzapine Lithium 3.7
Lamotrigine Venlafaxine 3.7
Olanzapine SSRI 3.6
Quetiapine Valproic acid 3.4
Mirtazapine Venlafaxine 3.4
Lamotrigine Lithium 3.3
Valproic acid Olanzapine 3.2
Lamotrigine Mirtazapine 3.2
b.
SSRI Quetiapine Lithium 1.7%
SSRI Quetiapine Lamotrigine 1.3
SSRI Mirtazapine Lithium 1.2
SSRI Mirtazapine Valproic acid 1.2
SSRI Mirtazapine Venlafaxine 1.2
Lithium Mirtazapine Venlafaxine 1.2
SSRI Olanzapine Lithium 1.1
Lithium Quetiapine Venlafaxine 1.1
Lithium Quetiapine Lamotrigine 1.1

Table  3a and b: Most frequent combinations (> 3% and > 1%, respectively) of at least two substances (Table  3a) and three substances (Table  3b) in percent (%) of all patients with bipolar depression (1994–2009).

Haeberle et al.

Haeberle et al. BMC Psychiatry 2012 12:153   doi:10.1186/1471-244X-12-153

Open Data